Cadrenal Therapeutics, Inc. (CVKD) Income Statement
CVKD 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCVKD revenue and net income
CVKD growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CVKD quarterly EPS vs estimates
Cadrenal Therapeutics beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 9, 2026 (estimate $-0.91).
CVKD income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $1,880 | $1,980 | $1,266 |
| Gross profit | — | −$1,880 | −$1,980 | −$1,266 |
| Research & development | $4.1M | $4.2M | $4.1M | $392,859 |
| Sales, general & admin | $9.4M | $6.8M | $3.5M | — |
| Total operating expenses | $13.5M | $11.0M | $7.6M | $2.7M |
| Operating income | −$13.5M | −$11.0M | −$7.6M | −$2.7M |
| Interest income | $223,815 | $309,251 | $249,092 | — |
| Interest expense | — | $0 | $17,101 | $107,105 |
| Income before taxes | −$13.2M | −$10.7M | −$8.4M | −$6.7M |
| Income taxes | — | — | −$165,915 | $4 |
| Net income | −$13.2M | −$10.7M | −$8.4M | −$6.7M |
| EBITDA | −$13.2M | −$10.6M | −$8.3M | −$6.6M |
| EPS (diluted) | −$6.68 | −$8.48 | −$8.10 | −$0.91 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $2,134 | $0 | $0 | $0 | $2,768 | $0 |
| Cost of revenue | — | $555 | $555 | $401 | $401 | $5,517 | $1,067 | $407 | $470 | $597 | $597 | $597 |
| Gross profit | — | −$555 | −$555 | −$401 | −$401 | −$5,517 | $1,067 | −$407 | −$470 | −$597 | $2,171 | −$597 |
| Research & development | $705,151 | $771,508 | $666,323 | $688,465 | $1.1M | $1.7M | $1.5M | $784,646 | $1.3M | $629,025 | $361,127 | $243,948 |
| Sales, general & admin | $2.6M | $1.7M | $2.4M | $2.0M | $2.7M | $2.3M | $2.7M | $1.7M | $1.2M | $1.1M | $902,107 | $898,051 |
| Total operating expenses | $3.3M | $2.5M | $3.1M | $2.7M | $3.7M | $3.9M | $4.3M | $2.5M | $2.5M | $1.8M | $1.3M | $1.1M |
| Operating income | −$3.3M | −$2.5M | −$3.1M | −$2.7M | −$3.7M | −$3.9M | −$4.3M | −$2.5M | −$2.5M | −$1.8M | −$1.3M | −$1.1M |
| Interest income | $17,835 | $17,838 | $26,116 | $48,098 | $67,004 | $82,596 | $91,159 | $52,129 | $73,636 | $92,327 | $119,771 | $106,145 |
| Interest expense | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $13,567 | $0 |
| Income before taxes | −$3.3M | −$2.5M | −$3.0M | −$2.7M | −$3.7M | −$3.8M | −$4.2M | −$2.4M | −$2.4M | −$1.7M | −$1.1M | −$1.0M |
| Income taxes | — | — | — | — | — | — | — | — | — | $3 | $3 | $106,145 |
| Net income | −$3.3M | −$2.5M | −$3.0M | −$2.7M | −$3.7M | −$3.8M | −$4.2M | −$2.4M | −$2.4M | −$1.7M | −$1.1M | −$1.0M |
| EBITDA | −$3.3M | −$2.5M | −$3.0M | −$2.7M | −$3.7M | −$3.8M | −$4.2M | −$2.4M | −$2.4M | −$1.7M | −$1.1M | −$1.0M |
| EPS (diluted) | −$1.14 | −$1.04 | −$1.41 | −$1.31 | −$1.87 | −$2.09 | −$2.55 | −$2.18 | −$2.25 | −$1.50 | −$0.05 | −$0.08 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | 78.4% | — |
| Operating margin | — | — | — | — | — | — | −200,488.7% | — | — | — | −45,658.6% | — |
| Net margin | — | — | — | — | — | — | −196,216.9% | — | — | — | −41,331.6% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CVKD's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CVKD financial results
Cadrenal Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $13.2 million. Diluted earnings per share came to −$6.68.
See the CVKD stock overview for the latest quote and news, or the CVKD chart for price history and technical indicators.
CVKD income statement FAQ
Does Cadrenal Therapeutics have revenue?
Cadrenal Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Cadrenal Therapeutics profitable?
No. Cadrenal Therapeutics reported a net loss of $13.2 million in fiscal 2025.
How much does Cadrenal Therapeutics spend on research and development?
Cadrenal Therapeutics spent $4.1 million on research and development in fiscal 2025.
What are Cadrenal Therapeutics's earnings per share?
Cadrenal Therapeutics earned $-6.68 per diluted share in fiscal 2025, compared with $-8.48 a year earlier.
When will Cadrenal Therapeutics report its next earnings?
Cadrenal Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.
When does Cadrenal Therapeutics's fiscal year end?
Cadrenal Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.